CPA
BMY icon

Cardiff Park Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cardiff Park Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,794
Closed -$215K – 319
2022
Q2 		$215K Buy
+2,794
New +$213K 0.03% 222

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cardiff Park Advisors's BMY Position: Q3 2022 in Review

Cardiff Park Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 2,794 shares — an estimated $215K sold.

Cardiff Park Advisors first reported a position in BMY in Q2 2022 and held it in 1 quarter. The position peaked at $215K in Q2 2022. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

  • Cardiff Park Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
  • Cardiff Park Advisors sold 2,794 Bristol-Myers Squibb shares in Q3 2022, an estimated $215K.
  • Cardiff Park Advisors first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 1 quarter.
  • Cardiff Park Advisors's Bristol-Myers Squibb position peaked at $215K in Q2 2022.
  • 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Cardiff Park Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.